Insider Trading activities of Avanir Pharmaceuticals insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Avanir Pharmaceuticals since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Avanir Pharmaceuticals since year 2005. Table 2 shows the detailed insider transactions of Avanir Pharmaceuticals since 2005. The reporting company's ticker symbol is AVNR. The reporting company's CIK number is 858803.
The total value of stock buying since 2005 is $5,727,916.
The total value of stock sales since 2005 is $111,785,727.
The total value of stock option exercises since 2005 is $1,379,703.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Avanir Pharmaceuticals (AVNR).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2014-12 0 $0 328,965 $5,573,979 257,451 $480,850
2014-11 0 $0 15,000 $225,000 0 $0
2014-10 0 $0 38,073 $448,177 0 $0
2014-09 0 $0 80,000 $800,999 0 $0
2014-08 0 $0 11,780 $63,735 0 $0
2014-05 0 $0 493,255 $2,475,034 0 $0
2013-12 10,000 $28,000 37,935 $101,081 0 $0
2013-11 10,000 $41,900 4,385 $18,136 0 $0
2013-09 0 $0 21,094 $88,974 21,094 $39,023
2013-08 0 $0 15,500 $74,989 0 $0
2013-05 0 $0 328,138 $1,071,826 273,138 $202,659
2012-12 10,000 $24,600 21,095 $53,721 0 $0
2012-09 0 $0 65,000 $226,850 65,000 $34,450
2012-06 0 $0 190,125 $664,867 0 $0
2012-05 2,700 $7,992 0 $0 0 $0
2012-03 18,000 $47,359 0 $0 0 $0
2011-12 0 $0 20,171 $47,799 0 $0
2011-11 0 $0 310,275 $807,075 310,275 $223,189
2011-09 0 $0 100,000 $275,000 0 $0
2011-01 0 $0 10,000 $40,500 0 $0
2010-12 0 $0 266,310 $1,080,685 242,650 $175,857
2010-11 0 $0 13,707,029 $64,886,473 0 $0
2010-10 0 $0 1,986,785 $9,178,348 0 $0
2010-09 0 $0 72,874 $204,900 0 $0
2010-08 0 $0 113,250 $342,696 28,250 $29,380
2010-07 0 $0 175,000 $613,310 0 $0
2010-06 0 $0 50,000 $119,100 0 $0
2010-05 0 $0 65,906 $201,342 0 $0
2010-04 0 $0 50,000 $162,459 0 $0
2010-03 0 $0 45,518 $110,277 0 $0
2010-01 0 $0 35,025 $67,138 0 $0
2009-12 0 $0 37,335 $68,136 0 $0
2009-10 0 $0 1,778,992 $4,105,249 0 $0
2009-09 2,000 $4,360 2,000 $4,200 0 $0
2009-08 0 $0 1,176,370 $4,248,378 0 $0
2009-07 0 $0 411,366 $956,554 0 $0
2009-02 36,900 $15,902 0 $0 0 $0
2008-10 300,003 $144,790 0 $0 0 $0
2008-09 1,377,083 $1,205,570 0 $0 0 $0
2008-08 484,870 $468,485 0 $0 0 $0
2006-05 26,600 $243,368 1,258,242 $12,318,188 50,000 $108,500
2006-03 0 $0 0 $0 3,250 $25,795
2006-02 1,000 $15,590 3,600 $60,552 5,000 $60,000
2005-10 566,038 $1,500,000 0 $0 0 $0
2005-04 900,000 $1,980,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Avanir Pharmaceuticals insiders (AVNR)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2014-12-18 Siffert Joao Md (SVP, R&D) Sale 15,505 16.93 262,499
2014-12-18 Siffert Joao Md (SVP, R&D) Option Ex 32,291 2.59 83,633
2014-12-18 Ocampo Christine (Vice President, Finance) Sale 5,780 16.93 97,855
2014-12-17 Katkin Keith (President and CEO) Sale 62,520 16.93 1,058,463
2014-12-16 Ocampo Christine (Vice President, Finance) Sale 30,000 16.94 508,200
2014-12-16 Ocampo Christine (Vice President, Finance) Option Ex 30,000 3.38 101,550
2014-12-15 Katkin Keith (President and CEO) Sale 215,160 16.95 3,646,962
2014-12-15 Katkin Keith (President and CEO) Option Ex 195,160 1.52 295,667
2014-11-28 Palekar Rohan (SVP & Chief Commercial Officer) Sale 15,000 15.00 225,000
2014-10-24 Siffert Joao Md (SVP, R&D) Sale 8,426 11.80 99,426
2014-10-24 Katkin Keith (President and CEO) Sale 27,567 11.76 324,187
2014-10-24 Ocampo Christine (Vice President, Finance) Sale 2,080 11.81 24,564
2014-09-15 Palekar Rohan (SVP & Chief Commercial Officer) Sale 25,000 11.25 281,250
2014-09-15 Ocampo Christine (Vice President, Finance) Sale 55,000 9.45 519,749
2014-08-26 Ocampo Christine (Vice President, Finance) Sale 2,110 6.10 12,871
2014-08-01 Katkin Keith (President and CEO) Sale 9,670 5.26 50,864
2014-05-28 Siffert Joao Md (SVP, R&D) Sale 13,547 5.18 70,173
2014-05-28 Katkin Keith (President and CEO) Sale 442,212 5.01 2,215,482
2014-05-16 Ocampo Christine (Vice President, Finance) Sale 11,900 4.88 58,072
2014-05-14 Ocampo Christine (Vice President, Finance) Sale 25,596 5.13 131,307
2013-12-18 Siffert Joao Md (SVP, R&D) Sale 5,970 2.63 15,713
2013-12-18 Katkin Keith (President and CEO) Sale 29,515 2.67 78,923
2013-12-18 Ocampo Christine (Vice President, Finance) Sale 2,450 2.63 6,445
2013-12-17 Palekar Rohan (SVP & Chief Commercial Officer) Buy 10,000 2.80 28,000
2013-11-04 Palekar Rohan (SVP & Chief Commercial Officer) Buy 10,000 4.19 41,900
2013-11-01 Katkin Keith (President and CEO) Sale 4,385 4.14 18,136
2013-09-18 Siffert Joao Md (SVP, R&D) Sale 21,094 4.22 88,974
2013-09-18 Siffert Joao Md (SVP, R&D) Option Ex 21,094 1.85 39,023
2013-08-02 Katkin Keith (President and CEO) Sale 15,500 4.84 74,989
2013-05-15 Katkin Keith (President and CEO) Sale 250,438 3.26 816,427
2013-05-15 Katkin Keith (President and CEO) Option Ex 215,438 .70 151,883
2013-05-15 Ocampo Christine (Vice President, Finance) Sale 77,700 3.29 255,399
2013-05-15 Ocampo Christine (Vice President, Finance) Option Ex 57,700 .88 50,776
2012-12-13 Palekar Rohan (SVP & Chief Commercial Officer) Buy 10,000 2.46 24,600
2012-12-03 Katkin Keith (President and CEO) Sale 18,250 2.55 46,464
2012-12-03 Ocampo Christine (Vice President, Finance) Sale 2,845 2.55 7,257
2012-09-17 Ocampo Christine (Vice President, Finance) Sale 65,000 3.49 226,850
2012-09-17 Ocampo Christine (Vice President, Finance) Option Ex 65,000 .53 34,450
2012-06-25 Katkin Keith (President and CEO) Sale 190,125 3.50 664,867
2012-05-10 Siffert Joao Md (SVP, R&D) Buy 2,700 2.96 7,992
2012-03-06 Katkin Keith (President and CEO) Buy 10,000 2.61 26,090
2012-03-06 Ocampo Christine (Vice President, Finance) Buy 3,000 2.60 7,794
2012-03-06 Mathews Charles (Director) Buy 5,000 2.70 13,475
2011-12-02 Katkin Keith (President and CEO) Sale 17,495 2.37 41,428
2011-12-02 Ocampo Christine (Vice President, Finance) Sale 2,676 2.38 6,371
2011-11-17 Katkin Keith (President and CEO) Sale 109,012 2.59 282,668
2011-11-17 Katkin Keith (President and CEO) Option Ex 109,012 .70 76,853
2011-11-16 Katkin Keith (President and CEO) Sale 109,013 2.59 282,343
2011-11-16 Katkin Keith (President and CEO) Option Ex 109,013 .53 57,776
2011-11-11 Ocampo Christine (Vice President, Finance) Sale 92,250 2.62 242,064
2011-11-11 Ocampo Christine (Vice President, Finance) Option Ex 92,250 .96 88,560
2011-09-09 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 100,000 2.75 275,000
2011-01-05 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 10,000 4.05 40,500
2010-12-06 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 10,000 3.80 38,000
2010-12-06 Ocampo Christine (Vice President, Finance) Sale 13,660 3.79 51,771
2010-12-03 Ocampo Christine (Vice President, Finance) Sale 23,350 4.03 94,100
2010-12-03 Ocampo Christine (Vice President, Finance) Option Ex 23,350 1.31 30,588
2010-12-02 Katkin Keith (President and CEO) Sale 195,300 4.08 797,214
2010-12-02 Katkin Keith (President and CEO) Option Ex 195,300 .53 103,509
2010-12-02 Ocampo Christine (Vice President, Finance) Sale 24,000 4.15 99,600
2010-12-02 Ocampo Christine (Vice President, Finance) Option Ex 24,000 1.74 41,760
2010-11-09 Steinmetz Michael (10% Owner) Sale 1,200,000 4.81 5,774,400
2010-11-08 Steinmetz Michael (10% Owner) Sale 44,626 5.10 227,592
2010-11-05 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 10,000 4.76 47,560
2010-11-05 Steinmetz Michael (10% Owner) Sale 997,716 4.80 4,792,029
2010-11-03 Steinmetz Michael (10% Owner) Sale 4,200,318 4.52 18,998,037
2010-11-02 Steinmetz Michael (10% Owner) Sale 1,290,871 4.49 5,799,883
2010-11-01 Katkin Keith (President and CEO) Sale 20,000 5.70 114,000
2010-11-01 Steinmetz Michael (10% Owner) Sale 2,478,142 5.36 13,272,928
2010-10-29 Steinmetz Michael (10% Owner) Sale 1,424,947 5.06 7,215,931
2010-10-11 Steinmetz Michael (10% Owner) Sale 311,000 3.52 1,093,476
2010-10-08 Steinmetz Michael (10% Owner) Sale 240,838 3.47 836,671
2010-10-05 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 10,000 3.23 32,270
2010-09-07 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 10,000 2.70 27,030
2010-09-01 Katkin Keith (President and CEO) Sale 62,874 2.83 177,870
2010-08-31 Katkin Keith (President and CEO) Sale 40,000 2.86 114,520
2010-08-18 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 35,000 3.08 107,660
2010-08-11 Ocampo Christine (Vice President, Finance) Sale 28,250 3.10 87,716
2010-08-11 Ocampo Christine (Vice President, Finance) Option Ex 28,250 1.04 29,380
2010-08-05 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 10,000 3.28 32,800
2010-07-13 Steinmetz Michael (10% Owner) Sale 165,000 3.53 583,110
2010-07-07 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 10,000 3.02 30,200
2010-06-07 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 50,000 2.38 119,100
2010-05-03 Katkin Keith (President and CEO) Sale 65,906 3.06 201,342
2010-04-30 Katkin Keith (President and CEO) Sale 40,000 3.31 132,360
2010-04-08 Katkin Keith (President and CEO) Sale 10,000 3.01 30,099
2010-03-29 Katkin Keith (President and CEO) Sale 30,000 2.60 78,000
2010-03-16 Ocampo Christine (Vice President, Finance) Sale 15,518 2.08 32,277
2010-01-05 Katkin Keith (President and CEO) Sale 15,025 1.94 29,178
2010-01-04 Katkin Keith (President and CEO) Sale 20,000 1.90 37,960
2009-12-15 Katkin Keith (President and CEO) Sale 37,335 1.82 68,136
2009-10-13 Schreiber Alain (10% Owner) Sale 547,135 2.23 1,220,111
2009-10-12 Schreiber Alain (10% Owner) Sale 427,145 2.12 905,547
2009-10-09 Schreiber Alain (10% Owner) Sale 804,712 2.46 1,979,591
2009-09-15 Kaye Randall (Sr. VP, Chief Medical Officer) Sale 2,000 2.10 4,200
2009-09-11 Kaye Randall (Sr. VP, Chief Medical Officer) Buy 2,000 2.18 4,360
2009-08-11 Vivo Ventures Vi, Llc (10% Owner) Sale 282,250 3.71 1,047,429
2009-08-11 Schreiber Alain (10% Owner) Sale 894,120 3.58 3,200,949
2009-07-31 Vivo Ventures Vi, Llc (10% Owner) Sale 1,400 2.20 3,080
2009-07-30 Vivo Ventures Vi, Llc (10% Owner) Sale 142,366 2.29 326,445
2009-07-29 Vivo Ventures Vi, Llc (10% Owner) Sale 145,500 2.28 331,303
2009-07-28 Vivo Ventures Vi, Llc (10% Owner) Sale 122,100 2.42 295,726
2009-02-24 Katkin Keith (President and CEO) Buy 15,000 .44 6,525
2009-02-24 Ocampo Christine (Vice President, Finance) Buy 11,900 .43 5,117
2009-02-23 Kaye Randall (Sr. VP, Chief Medical Officer) Buy 10,000 .43 4,260
2008-10-22 Schreiber Alain (10% Owner) Buy 10,600 .48 5,088
2008-10-15 Schreiber Alain (10% Owner) Buy 6,465 .49 3,167
2008-10-14 Schreiber Alain (10% Owner) Buy 32,300 .50 16,150
2008-10-10 Schreiber Alain (10% Owner) Buy 73,551 .45 33,097
2008-10-09 Schreiber Alain (10% Owner) Buy 41,385 .48 19,864
2008-10-08 Schreiber Alain (10% Owner) Buy 114,384 .50 57,192
2008-10-07 Schreiber Alain (10% Owner) Buy 21,318 .48 10,232
2008-09-17 Schreiber Alain (10% Owner) Buy 413,217 .80 330,573
2008-09-16 Schreiber Alain (10% Owner) Buy 17,387 .76 13,214
2008-09-15 Schreiber Alain (10% Owner) Buy 244,449 .85 207,781
2008-09-10 Schreiber Alain (10% Owner) Buy 48,103 .91 43,773
2008-09-09 Schreiber Alain (10% Owner) Buy 146,400 .92 134,688
2008-09-08 Schreiber Alain (10% Owner) Buy 125,000 .95 118,750
2008-09-04 Schreiber Alain (10% Owner) Buy 52,113 .95 49,507
2008-09-03 Schreiber Alain (10% Owner) Buy 6,864 .93 6,383
2008-09-02 Schreiber Alain (10% Owner) Buy 323,550 .93 300,901
2008-08-27 Schreiber Alain (10% Owner) Buy 89,447 .95 84,974
2008-08-15 Schreiber Alain (10% Owner) Buy 114,032 .95 108,330
2008-08-14 Schreiber Alain (10% Owner) Buy 6,051 .90 5,445
2008-08-07 Schreiber Alain (10% Owner) Buy 182,760 .98 179,104
2008-08-06 Schreiber Alain (10% Owner) Buy 800 .90 720
2006-05-31 Podlesak Dennis (Director) Buy 1,000 9.90 9,905
2006-05-31 Orbimed Capital Ii Llc (Director) Sale 629,121 9.79 6,159,094
2006-05-31 Silverstein Jonathan (Director) Sale 629,121 9.79 6,159,094
2006-05-30 Berg James E (Vice President, Clinical) Option Ex 37,500 2.88 108,000
2006-05-26 Kaye Randall (VP of Medical Affairs) Buy 2,500 9.96 24,892
2006-05-26 Hanson Gregory P (Vice President, CAO) Buy 1,100 9.67 10,639
2006-05-25 Katkin Keith (Sr. V.P. of Sales & Marketing) Buy 2,500 8.99 22,475
2006-05-25 Puntoriero Michael J (Senior VP, Finance, CFO) Buy 7,500 9.02 67,687
2006-05-25 Brandt Eric (President, CEO & Director) Buy 11,000 8.98 98,780
2006-05-25 Emanuele Robert Martin (V P, Business Development) Buy 1,000 8.99 8,990
2006-05-08 Kaye Randall (Chief Medical Officer) Option Ex 12,500 .04 500
2006-03-01 Berg James E (VP, Clinical & Reg. Affairs) Option Ex 3,250 7.94 25,795
2006-02-17 Sircar Jagadish C (VP of Drug Discovery) Sale 3,600 16.82 60,552
2006-02-17 Sircar Jagadish C (VP of Drug Discovery) Option Ex 5,000 12.00 60,000
2006-02-14 Mazzo David J (Director) Buy 1,000 15.59 15,590
2005-10-20 Silverstein Jonathan (Director) Buy 566,038 2.65 1,500,000
2005-04-08 Silverstein Jonathan (Director) Buy 900,000 2.20 1,980,000

Insider trading activities including stock purchases, stock sales, and option exercises of AVNR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Avanir Pharmaceuticals (symbol AVNR, CIK number 858803) see the Securities and Exchange Commission (SEC) website.